Gufic Biosciences Q2 FY27: standalone revenue Rs 288.40 cr, PAT up 57.3%
For the quarter ended 30-Sep-26, standalone revenue was Rs 288.40 cr and PAT rose to Rs 23.49 cr from Rs 14.94 cr a year earlier.
Key takeaways
- Revenue from operations Rs 288.40 cr vs Rs 230.42 cr a year earlier.
- Total Income Rs 289.53 cr vs Rs 232.51 cr in the corresponding quarter.
- Total Expenses Rs 258.03 cr vs Rs 211.98 cr in Q2 FY26.
- PAT Rs 23.49 cr vs Rs 14.94 cr in the year-ago quarter.
- Basic and diluted EPS Rs 2.34 vs Rs 1.49 a year earlier.
Quarter Ended 30-Sep-26 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 288.40 cr | Rs 230.42 cr | +25.2% |
| PAT | Rs 23.49 cr | Rs 14.94 cr | +57.3% |
| EPS | Rs 2.34 | Rs 1.49 | +57.0% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 8.14% of revenue, up 166 bps from 6.48%.
- Revenue rose 25.2% while total expenses rose 21.7%.
- Cost of materials accounted for Rs 43.45 cr of the Rs 46.05 cr rise in total expenses (94%).
- Cost of materials took 54.4% of revenue, against 49.2% a year earlier.
Key numbers (standalone, Q2 FY27 vs Q2 FY26)
All figures are from the standalone statement of financial results for the quarter ended 30-Sep-26 and the corresponding quarter ended 30-Sep-25.
- Revenue from operations: Rs 288.40 cr (Q2 FY27) vs Rs 230.42 cr (Q2 FY26)
- Other income: Rs 1.12 cr vs Rs 2.09 cr
- Total Income: Rs 289.53 cr vs Rs 232.51 cr
- Cost of materials consumed: Rs 156.92 cr vs Rs 113.47 cr
- Purchase of stock-in-trade: Rs 14.60 cr vs Rs 25.69 cr
- Changes in inventories of finished goods, work-in-progress and stock-in-trade: Rs (36.07) cr vs Rs (39.25) cr
- Employee benefits expense: Rs 45.43 cr vs Rs 37.45 cr
- Finance cost: Rs 10.44 cr vs Rs 9.58 cr
- Depreciation and amortisation expense: Rs 7.73 cr vs Rs 7.77 cr
- Other expenses: Rs 58.98 cr vs Rs 57.27 cr
- Total Expenses: Rs 258.03 cr vs Rs 211.98 cr
- Total Profit before exceptional items and tax (PBT): Rs 31.49 cr vs Rs 20.53 cr
- Total Profit Before Tax: Rs 31.49 cr vs Rs 20.53 cr
- Total Tax Expenses: Rs 8.00 cr vs Rs 5.59 cr
- Net Profit for the period from continuing operations (PAT): Rs 23.49 cr vs Rs 14.94 cr
- Total Profit for period: Rs 23.49 cr vs Rs 14.94 cr
- Paid-up equity share capital: Rs 10.03 cr vs Rs 10.03 cr
- Face value of equity share capital: Rs 1.00 vs Rs 1.00
- Basic earnings per share: Rs 2.34 vs Rs 1.49
- Diluted earnings per share: Rs 2.34 vs Rs 1.49
For the quarter ended 30-Sep-26, Gufic Biosciences’ standalone revenue from operations, as reported in the statement of financial results, increased to Rs 288.40 cr from Rs 230.42 cr in the corresponding quarter ended 30-Sep-25. Total Income moved to Rs 289.53 cr from Rs 232.51 cr over the same period.
On the cost side, cost of materials consumed rose to Rs 156.92 cr from Rs 113.47 cr, while purchase of stock-in-trade declined to Rs 14.60 cr from Rs 25.69 cr. Changes in inventories of finished goods, work-in-progress and stock-in-trade stood at Rs (36.07) cr compared with Rs (39.25) cr a year earlier. Employee benefits expense increased to Rs 45.43 cr from Rs 37.45 cr, and finance cost rose to Rs 10.44 cr from Rs 9.58 cr. Depreciation and amortisation expense was Rs 7.73 cr versus Rs 7.77 cr, and other expenses were Rs 58.98 cr versus Rs 57.27 cr.
Total Expenses for the quarter were Rs 258.03 cr, up from Rs 211.98 cr in the corresponding prior period. Total Profit before exceptional items and tax (labelled as "Total Profit before exceptional Items and tax (1-2)") increased to Rs 31.49 cr from Rs 20.53 cr, and Total Profit Before Tax was also Rs 31.49 cr versus Rs 20.53 cr.
After Total Tax Expenses of Rs 8.00 cr (vs Rs 5.59 cr a year earlier), Net Profit for the period from continuing operations was Rs 23.49 cr, compared with Rs 14.94 cr in the same quarter of the previous year. Basic and diluted earnings per share for the quarter were both reported at Rs 2.34, up from Rs 1.49 in the corresponding quarter, on an unchanged paid-up equity share capital of Rs 10.03 cr with a face value of Rs 1.00 per share.
Track Gufic Biosciences Ltd
Cruxal reads every Gufic Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.